Kazia Therapeutics’ paxalisib reduced tumor burden by 52% in a preclinical MSS/pMMR colorectal cancer model, while combining it with immunotherapy reduced tumor Volume an additional 50%. The findings matter because Kazia plans a Phase 2 study, with enrollment expected to begin in the first quarter of 2027.

Key Highlights

  • Kazia Therapeutics reported that paxalisib reduced tumor burden by 52% in a preclinical MSS/pMMR colorectal cancer model.
  • It reports preclinical efficacy, tolerability, biomarker work, and a Patent filing, while noting that its ADSs trade under KZIA.
  • And Share Registration The combination result carried a p-value of 0.022.

KAZIA THERAPEUTICS LTD (NASDAQ: KZIA) said paxalisib reduced total tumor burden by 52% in a preclinical model of MSS/pMMR colorectal cancer, with a result of p=0.035. A separate experiment found that adding the drug to immunotherapy cut tumor volume an additional 50% versus immunotherapy alone, while treatment was well tolerated in both studies.

Paxalisib Data

and Share Registration The combination result carried a p-value of 0.022. Kazia is developing a biomarker program to identify patients most likely to respond, measure early biological changes and support biomarker-led clinical development in pMMR colorectal cancer. Emerging biomarker findings and the preclinical results have also been incorporated into a new patent filing covering potential uses of paxalisib in colorectal cancer. Kazia’s ADSs trade on the Nasdaq Capital Market under the symbol KZIA.